Hansen John A, Petersdorf Effie W, Lin Ming-Tseh, Wang Steven, Chien Jason W, Storer Barry, Martin Paul J
Division of Clinical Research, Fred Hutchinson Cancer Research Center, University of Washington, 1100 Fairview Ave N, D2-100, P.O. Box 19024, Seattle, WA 98109-1024, USA.
Immunol Res. 2008;41(1):56-78. doi: 10.1007/s12026-007-0043-x.
Successful outcome following hematopoietic stem cell transplantation (HSCT) is ultimately determined by the ability to achieve sustained engraftment and immune reconstitution, control of graft-versus-host disease (GVHD), and in patients with hematological malignancy the complete eradication of abnormal or malignant cells. GVHD, which can be a serious and fatal complication, is an immune reaction that is initiated by donor T cells in response to recipient alloantigens. Genetic variation in both patient and donor can significantly affect transplant outcome by causing disparity for transplant antigens, and by altering the function of immune response genes that control cellular activation and inflammation. Genetic variation can modulate the intensity of the alloimmune response, the risk of transplant-related organ toxicity and mortality, and may also affect the development of tolerance and the reconstitution of the immune system following HSCT.
造血干细胞移植(HSCT)后的成功结局最终取决于实现持续植入和免疫重建的能力、移植物抗宿主病(GVHD)的控制,以及对于血液系统恶性肿瘤患者而言,异常或恶性细胞的完全清除。GVHD可能是一种严重且致命的并发症,是由供体T细胞针对受体同种异体抗原引发的免疫反应。患者和供体的基因变异可通过导致移植抗原的差异,以及改变控制细胞活化和炎症的免疫反应基因的功能,从而显著影响移植结局。基因变异可调节同种免疫反应的强度、移植相关器官毒性和死亡率的风险,还可能影响HSCT后耐受性的发展和免疫系统的重建。